Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications and vitamin drops. The Health Care segment is engaged in the manufacture and sale of general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. The Company has 49 subsidiaries and 15 associated companies.

SIGA Technologies was founded in 1995 and is headquartered in New York, New York. SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of anti-infectives and antibiotics for the prevention and treatment of serious infectious diseases. SIGA company focus on products for use in defense against biological warfare agents, such as smallpox, arenaviruses (hemorrhagic fevers), and other category A viral agents. Its lead product, ST-246, is an orally administered anti-viral drug that targets orthopox viruses. SIGA's product candidates also include ST-294 and ST-193, which demonstrates antiviral activity in cell culture assays against arenavirus pathogens; and ST-669, a broad spectrum antiviral candidate, for various viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. In addition, it also has four drug series in the pre-clinical development stage, including ST-610 and ST-148 for dengue virus of the genus Flavivirus. SIGA company has license agreements, collaborative research arrangements, and contracts with National Institutes of Health and the United States Air Force.

DURECT Corporation was founded in 1998 and is based in Cupertino, California. DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for pain, central nervous system, disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. The company's products include POSIDUR, a release formulation of bupivacaine under Phase IIb clinical trial, which is used for the treatment of post-surgical pain; and ELADUR, a transdermal bupivacaine patch under Phase IIb clinical trial that provides continuous delivery of bupivacaine for up to three days from a single application, as well as is used for the treatment of pain associated with post-herpetic neuralgia. DURECT Corporation also offers Remoxy, an oral oxycodone gelatin capsule under development with pain therapeutics; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch under development, which provides continuous delivery of sufentanil for a period of up to seven days from a single application. In addition, the company offers CHRONOGESIC (sufentanil), a pain therapy system; and ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. Further, it designs, develops, and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients for use as raw materials in their products.

Hyaluron, Inc. company specializes in aseptically filling syinges and vials with liquid and lyophilized (treated for preservation) products serving the medical and pharmaceutical markets. Hyaluron manufacturing facility can accomodate the needs of clients small and large, from pre-clincial batches to commercial scale development. Hyaluron's expertise also extends into scaling up formulations such as emulsions, viscous gels, suspensions, liposomes, and proteins which will eventually fill the vials and syringes of the company's clients. The company can fill about 150,000 syringes a day and 75,000 vials.

Fulcrum Pharma plc is a United Kingdom-based company. The Company is engaged in providing solutions for the development of therapeutic products. It provides regulatory expertise and resource throughout all stages of product development. The Company provides customized pharmacovigilance and risk management solutions. It provides support for product registration, launch and in market maintenance. It operates through eight offices across the United States, Europe and Japan. The Company’s subsidiaries include Fulcrum Pharma (Europe) Limited, Fulcrum Pharma Developments Limited, Quadramed Limited, Unicus Limited and Fulcrum Regulatory Limited.

Momenta Pharmaceuticals was founded in 2001 and is based in Cambridge, Massachusetts. Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. Its product candidates include M-Enoxaparin, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; and M118, an anticoagulant. The company also involves in developing generic or biosimilar glycoprotein products. Momenta Pharmaceuticals has collaborations with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002.

Qiagen N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands. Qiagen N.V. provides technologies and products for preanalytical sample preparation and linked molecular assay solutions worldwide. Its sample technologies are used to collect, stabilize, isolate, and purify deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from blood, bone, and tissue samples; and assay technologies are used to make specific target biomolecules, such as the DNA of a specific virus for subsequent detection and analysis. The company offers sample and assay consumable products that are used in plasmid, DNA purification; RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. It also provides PCR assays, which allow PCR-based detection of viral, bacterial and parasite, human, and animal pathogens, as well as pharmacogenomic genotyping; and various other products for research in the areas of epigenetics, gene expression, micro RNA, proteomics, RNAi, and applied testing and molecular diagnostics. In addition, the company offers automated systems that provide walk-away automation of sample and assay technologies in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks; QIAcube, which allows users in research in life sciences, applied testing, and molecular diagnostic to automate the processing of the company's consumable products; and instruments to OEM partners. Further, it provides custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production on a contract basis; and sells and/or licenses technology. The company serves researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories.

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States. The company's lead product candidate includes RDEA594, a product for the treatment of hyperuricemia and gout. Its other products comprise RDEA806 for the treatment of patients with HIV; and RDEA427, a second-generation NNRTI for the treatment of HIV, in a human micro-dose pharmacokinetic study. Ardea Biosciences is evaluating RDEA119, a non-ATP EK inhibitor, in a Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. It also develops RDEA436 for the treatment of inflammation. The company is based in San Diego, California.

Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases and other chronic debilitating diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery segment develops, manufactures and distributes biotherapeutics and biomaterial-based products, with a focus on products that meet medical needs in the orthopaedics and broader surgical areas. Hematologic Oncology segment develops, manufactures and distributes products for the treatment of cancer.

Elan Pharmaceuticals is part of the the brains behind the brawn of drugmaker Elan Corporation. The US-based subsidiary provides research and discovery services, such as the identification and development of new drug candidates, to its Irish parent, which specializes in treatments for neurological and autoimmune diseases, as well as severe pain and infectious disease medications. The company investigates possible treatments for diseases such as Alzheimer's disease, Parkinson's disease, and multiple myeloma. The subsidiary also handles marketing of Elan's approved products in the US, including multiple sclerosis/Crohn's disease treatment Tysabri and chronic pain medication Prialt.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.